DARE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Dare Bioscience Inc (DARE) is not a good buy for a beginner investor with a long-term strategy at this time. Despite the recent significant price increase, the overbought RSI, lack of positive financial performance, and absence of strong trading signals or catalysts suggest caution. The stock's technical indicators and financials do not align with a solid long-term investment opportunity.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is at 90.639, signaling an overbought condition. Moving averages are converging, suggesting indecision. The stock is trading near its resistance level (R1: 2.536), with limited upside potential in the short term.
NULL identified. No recent news or significant events to drive the stock higher.
The stock is overbought (RSI: 90.639). Financial performance is weak, with declining net income (-73.82% YoY) and EPS (-85.51% YoY). No significant hedge fund, insider, or congressional trading activity to indicate confidence in the stock.
In Q4 2025, revenue remained flat YoY at $1,023,676. Net income dropped significantly to -$1,441,718 (-73.82% YoY), and EPS fell to -0.1 (-85.51% YoY). Gross margin decreased to 71.1%, down 28.90% YoY. Overall, the company's financials indicate poor growth and profitability trends.
No analyst rating or price target changes available. Wall Street sentiment is neutral with no significant pros or cons identified.
